Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck is paying $700 million upfront plus up to $600 million in milestones to acquire global rights to Curon Biopharmaceutical's CD19xCD3 bispecific antibody CN201.
Legend Biotech's CEO Ying Huang is evaluating the company's business amid geopolitical risks and M&A rumors, while focusing on expanding Carvykti manufacturing capacity.
Amgen's FDA application for lung cancer drug Imdelltra had a large number of underreported adverse events, prompting a full reevaluation of safety data.
Legend Biotech is assessing potential impacts of the draft BIOSECURE Act but does not believe it will be directly affected.
Carvykti sales reached $186 million in Q2 2024, with Legend and J&J working to expand manufacturing capacity.
Amgen identified 393 previously unreported adverse events across all clinical trial sites for Imdelltra after an FDA inspection uncovered reporting deficiencies.
Legend Biotech plans to open a new 31,000-square-foot R&D facility in Philadelphia in Q3 2025 to advance next-generation cell therapies.